drug
ripretinib
Marketedupdated 3mo agoby Deciphera Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ripretinib
- phase2A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- phase2A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- phase3A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- phase3A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- —Ripretinib (QINLOCK®) According to Current SmPC
- phase1A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 15, 2027
269 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (41)
- Oct 6, 2042method-of-use (U-3714)US 11779572
- Feb 8, 2041method-of-use (U-3897)US 11969414
- Dec 30, 2040formulationUS 11185535
- Dec 30, 2040formulationUS 11395818
- Dec 30, 2040formulationUS 11576903
- Dec 30, 2040formulationUS 11612591
- Dec 30, 2040formulationUS 11793795
- Dec 30, 2040formulationUS 11801237
- Dec 30, 2040formulationUS 11844788
- Dec 30, 2040formulationUS 11850240
- Dec 30, 2040formulationUS 11850241
- Dec 30, 2040formulationUS 11896585
- Dec 30, 2040formulationUS 11903933
- Dec 30, 2040formulationUS 11911370
- Dec 30, 2040formulationUS 11918564
- Dec 30, 2040method-of-use (U-3219)US 11969415
- Dec 30, 2040method-of-use (U-3957)US 12023328
- Dec 30, 2040method-of-use (U-3219)US 12064422
- Dec 30, 2040formulationUS 12213967
- Dec 30, 2040formulationUS 12213968
- Dec 30, 2040formulationUS 12226406
- Dec 30, 2040formulationUS 12318374
- Aug 12, 2040method-of-use (U-3153)US 10966966
- Aug 12, 2040method-of-use (U-3330)US 11266635
- Aug 12, 2040method-of-use (U-3381)US 11344536
- Aug 12, 2040method-of-use (U-3416)US 11426390
- Aug 12, 2040method-of-use (U-3423)US 11433056
- Aug 12, 2040method-of-use (U-3382)US 11529336
- Aug 12, 2040method-of-use (U-3442)US 11534432
- Aug 12, 2040method-of-use (U-3537)US 11576904
- Aug 12, 2040method-of-use (U-3750)US 11813251
- Aug 12, 2040method-of-use (U-3960)US 12023325
- Aug 12, 2040method-of-use (U-3959)US 12023326
- Aug 12, 2040method-of-use (U-3958)US 12023327
- Aug 12, 2040method-of-use (U-3153)US 12059410
- Aug 12, 2040method-of-use (U-3971)US 12059411
- Aug 12, 2040method-of-use (U-4183)US 12295944
- Aug 12, 2040method-of-use (U-4191)US 12318373
- May 15, 2034compositionUS 8461179
- Jun 7, 2032method-of-use (U-3219)US RE48731
- Jul 27, 2030compositionUS 81881133.9y
FDA exclusivities (1)
- May 15, 2027ODE-298Orphan Drug (7y)269d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that